• Omar S. Salih Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Iraq


Objective: Low permeability of rosuvastatin calcium faces a problem of low bioavailability (absolute bioavailability 20%) as its permeation is the rate limiting factor. Rosuvastatin calcium is a selective competitive inhibitor of HMG-CoA reductase and it lowers plasma cholesterol level. Aspirin is an anti-platelet agent with half-life of 6-7 h. Frequency of dosing of both drugs is high to maintain the desired plasma drug concentration so it is selected to formulate a sustained release tablet of aspirin and rosuvastatin calcium, which release the drug in a sustained manner over a period of time by using various polymers and study the effect of polymers on the release pattern of both drugs. This approach will also enhance the residence time of rosuvastatin calcium at the absorption site and enhance permeation by the effect of the polymers used and this in turn will enhance bioavailability.

Methods: Tablets contain aspirin plus rosuvastatin calcium were prepared by direct compression method. The sustained release of the tablets was obtained by using different polymers (xanthan gum, microcrystalline cellulose, HPMC K4M and chitosan) incorporated in the tablet and responsible for the release of both drugs from each tablet. Tablets were evaluated for weight variation, drug content, friability, hardness and thickness for all batches (F1 to F12). In-vitro dissolution was studied for all batches (F1 to F12) according to the type and ratio of each polymer used within these formulas i.e. (10 mg, 20 mg and 30 mg) respectively.

Results: The release of aspirin and rosuvastatin calcium from sustained release tablets varied according to the type and amount (ratio) of each polymer used. After the 7 h release study; (F1, F2, F3) that uses xanthan gum as the sustain release polymer showed the most sustained formulations than other polymers. The sustained release of drugs from tablet enhanced by increasing the amount of polymer, so F3 for example, which contain 30 mg xanthan gum had most sustained release than F1 and F2 which contain (10 mg and 20 mg) of the polymer respectively, this due to polymer related viscosity, swelling and binding mechanisms.

Conclusion: Using suitable polymer for sustained release will enhance the pharmacokinetics and efficacy of drugs and increase patient complains about combination therapy.


Keywords: Rosuvastatin calcium, Hyperlipidemia, Aspirin, Sustain release tablet, Polymers


Download data is not yet available.

Author Biography

Omar S. Salih, Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Iraq
department of pharmaceutics


1. Löbenberg, Raimar, Gordon L. Amidon. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000;50:3-12.
2. Aarti P, Jogiya CS, Chauhan, Prashant G Jogiya. Formulation and evaluation of sustained release tablets of aspirin and atorvastatin. Pharmtechmedica 2012;1:91-7.
3. Chavanpatil, Mahesh D. Novel sustained release, swellable and bioadhesive gastro retentive drug delivery system for ofloxacin. Int J Pharm 2006;316:86-92.
4. Kumar KP Sampath. Sustained release drug delivery system potential. Terminology 2012;1:46-56.
5. Tabandeh, Hosseinali, Seyed Alireza Mortazavi, Tina Bassir Guilani. Preparation of sustained-release matrix tablets of aspirin with ethylcellulose, eudragit RS100 and eudragit S100 and studying the release profiles and their sensitivity to tablet hardness. Iran J Pharm Res 2010;2:201-6.
6. Salih Omar S, Laith H Samein, Wedad K Ali. Formulation and in vitro evaluation of rosuvastatin calcium niosomes. Int J Pharm Pharm Sci 2013;Suppl 4:525-35.
7. Pather S Indiran. Sustained release theophylline tablets by direct compression: Part 1: formulation and in vitro testing. Int J Pharm 1998;164:1-10.
8. Basak, Subal Chandra, Kesevan Senthil Kumar, Murugesan Ramalingam. Design and release characteristics of sustained release tablet containing metformin HCl. Rev Bras Cienc Farm 2008;44:477-83.
9. Mohammad Saleem, Mohammad Shahin, Bijja. Evaluation of tablets by friability apparatus. Int J Res Pharm Chem 2014;4:837-40.
10. Emami, Jaber, Mona Tajeddin, Fatemeh Ahmadi. Preparation and in vitro evaluation of sustained-release matrix tablets of flutamide using synthetic and naturally occurring polymers. Iran J Pharm Res 2010;7:247-57.
11. Bushra, Rabia. Formulation development and optimization of ibuprofen tablets by direct compression method. Pak J Pharm Sci 2008;21:113-20.
12. Aulton ME. Pharmaceutics: the science of dosage form design. 1. ed. London: Churchill Livingstone; 1998.
13. Talukdar MM, R Kinget. Swelling and drug release behaviour of xanthan gum matrix tablets. Int J Pharm 1995;120:63-72.
14. Albhar, Ketan Gulabrao, Vaibhav Sudhakar Wagh, BB Chavan. Effect of HPMC K4M, HPMC K15M, sodium alginate and carbopol 934 in the formulation of carbonyl iron capsule. J Der Pharm Lett 2012;4:94-367.
15. Levina, Marina, Ali R, Rajabi‐Siahboomi. The influence of excipients on drug release from hydroxypropyl methylcellulose matrices. J Pharm Sci 2004;93:2746-54.
16. Kannan, Subramaniam. Formulation and evaluation of sustained release tablets of aceclofenac using hydrophilic matrix system. Int J PharmTech Res 2010;2:1775-80.
17. Thoorens, Gregory. Microcrystalline cellulose, a direct compression binder in a quality by design environment-A review. Int J Pharm 2014;473:64-72.
18. AL-Sokanee, Zeki N. Drug release study of nalidixic acid from the chitosan-carrageenan ionic matrix. Chemistry Department, College Science, Basrah University 2007;25:104-18.
19. Savaşer, Ayhan, Yalçın Özkan, Aşkın Işımer. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium. Il Farmaco 2005;60:171-7.
20. Ruckmani, Kandasamy, Veintramuthu Sankar. Formulation and optimization of zidovudine niosomes. AAPS PharmSciTech 2010;11;1119-27.
753 Views | 1904 Downloads
How to Cite
Salih, O. S. “STUDY THE SUSTAIN RELEASE EFFECT OF DIFFERENT POLYMERS USED IN THE FORMULATION OF ASPIRIN-ROSUVASTATIN TABLETS”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 12, Oct. 2015, pp. 166-72,
Original Article(s)